Organovo Holdings, Inc. v. Dimitrov

162 A.3d 102, 2017 WL 2417917, 2017 Del. Ch. LEXIS 95
CourtCourt of Chancery of Delaware
DecidedJune 5, 2017
DocketCA 10536-VCL
StatusPublished
Cited by65 cases

This text of 162 A.3d 102 (Organovo Holdings, Inc. v. Dimitrov) is published on Counsel Stack Legal Research, covering Court of Chancery of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Organovo Holdings, Inc. v. Dimitrov, 162 A.3d 102, 2017 WL 2417917, 2017 Del. Ch. LEXIS 95 (Del. Ct. App. 2017).

Opinion

OPINION

LASTER, Vice Chancellor.

Defendant Georgi Dimitrov moved to vacate the entry of default judgment against him. His motion is granted.

I. FACTUAL BACKGROUND

The facts are drawn from the Verified Complaint (the “Complaint”) and the materials submitted by the parties during post-default proceedings. A default judgment “deem[s] admitted all the well-pleaded *105 facts in the complaint.” 1 This decision also takes judicial notice of previous proceedings in a related action.

A. The Parties

Plaintiff Organovo Holdings, Inc. (“Or-ganovo” or the “Company”) is a Delaware corporation with its headquarters in San Diego, California. The Company designs and creates functional human tissues through its use of proprietary three-dimensional bioprinting technology. In July 2013, the Company listed its common stock on the New York Stock Exchange. In the months following its initial listing, the Company’s stock price fluctuated widely. Between October 2013 and March 2014, the Company’s stock price ranged between $5,55 per share and $12.75 per share, with an average trading price of $8.78.

Dimitrov is a man of mystery. In February 2014, he formed non-party Simeon Research, LLC (“Simeon”), a Delaware limited liability company. Shortly afterwards, he created a website for Simeon at the URL www.simeonresearch.com. He also secured for Simeon the Twitter handle @SimeonResearch. Simeon’s Twitter bio described its feed as “long/short analytical equity research.” 2

Simeon engaged in a single activity: publishing negative information about the Company. In March and April 2014, Dimi-trov published two reports in Simeon’s name. Dimitrov called attention to these reports by posting sixty-five comments on Simeon’s Twitter account.

B. The March Report

In March 2014, Dimitrov posted a fifty-seven page report on Simeon’s website titled “Organovo: Dissecting the Fairy Tale—Full Report” (the “March Report”). 3 Dimitrov styled the March Report to look like work product from a professional equity research firm. He created official-looking letterhead and included a standard anti-reliance disclaimer. The report claimed to be the product of “hundreds of hours of intensive research from hundreds of journal publications, never-before seen primary sources, and extensive industry interviews.” 4 It contained 189 footnotes citing public filings, news articles, and academic papers. It included numerous pictures and charts. Less professionally, it made extensive use of bold and underlined typeface, which this decision omits.

The beginning of the March Report summarized its key points.

• “Organovo’s bioprinting technology is not pivotal to tissue engineering or organ fabrication. Simeon Research publishes for the first time to the public the views expressed by Orga-novo’s scientific founder: bioprint-ing—‘it’s nothing, it’s a stupid exercise.’ ”
• “Organovo has misled investors in multiple instances about its technology, its competitive position, and what it can deliver.”
• “A number of companies and academics have developed bioprinters that have better capabilities than those of Organovo’s NovoGen biop-rinter.”
• “Organovo has failed to deliver on its promises a number of times in the past, and has experienced a wash-out of material partnerships.”
*106 • “Organovo’s liver tissue data is years behind competitors in the 3D liver toxicology market.”
• “Organovo’s intellectual capital has deteriorated significantly, as the founder exited and key scientistis left.”
• “The scientific consensus on organ printing is that the media has hyper-bolized it far and above reality while the public has bought in .... ”
• “Organovo has experienced a rabid run-up in price that is ineongruent with its real valuation, which we believe to be $1.35/share.” 5

The bulk of the March Report focused on the bioprinting industry’s lack of commercial promise and the Company’s technical inferiority to competitors in that field. It mixed in accusations that the Company’s management had misled investors and engaged in self-dealing.

Only the last three pages of the March Report analyzed the value of the Company’s stock. Much of this final section consisted of quotes from outside analysts. The only original valuation work appeared in the final two pages. Simeon ultimately valued Organovo based on an asset-based approach described in a single paragraph:

We have demonstrated that Organovo lacks a competitive moat—its bioprinting technology is just a “stupid exercise” in the words of its scientific founder and it has been eclipsed by other bioprinting manufacturers while its liver tissue is inferior to the product offerings of other companies. Given this, we think it would be fairly easy to replicate every tangible asset on which Organovo’s valuation is based—it thus makes a good basis for valuing the company. Bioprinters from a competing company. A warehouse. 35 scientists. $50M in cash. We will grant the exceedingly generous 5x multiple to Organovo’s $13.5M in R & D spent since inception. All of this brings us to = $120M. At the current diluted share count, Organovo would be valued at $1.35/share. We think this is a fair value and even generous given the cascade of red flags about the company and its management. 6

The Company responded to the March Report on its website. Among other things, the Company asserted that the report “was issued by or at the request of a short seller or short-sellers.” 7

C. The April Report

The March Report portended further publications. “This report encompasses roughly a third of the information Simeon Research has uncovered. Additional reports will follow in the coming weeks.” 8 In April 2014, Simeon published a second report on its website titled “Bargaining with the Devil: How Organovo Used Fraudulent Brokers and Promoters to Sell its Shares and Story” (the “April Report”). 9 Dimitrov prepared the April Report in the same style as the March Report.

The April Report asserted that the Company was defrauding its investors. The first sentence of the April Report stated, “Organovo has carried out one of the most successful penny stock promotions currently listed on a major exchange.” 10 The April Report summarized its support for this assertion as follows:

Free access — add to your briefcase to read the full text and ask questions with AI

Related

DBMP LLC v. Delaware Claims Processing Facility, LLC
Court of Chancery of Delaware, 2025
Watson v. Division of State Police
Superior Court of Delaware, 2025
Red Cat Holdings Inc v. Autonodyne LLC
Superior Court of Delaware, 2025
Coomer v. Byrne
M.D. Florida, 2025
JanCo FS 2, LLC v. ISS Facility Services, Inc.
Superior Court of Delaware, 2024
Winklevoss Capital Fund, LLC v. Shaw
Court of Chancery of Delaware, 2024
Paul Rivera v. Angkor Capital Limited
Court of Chancery of Delaware, 2024
Kun Jiang v. Haslet Park Homeowners Association
Court of Chancery of Delaware, 2024
Red Cat Holdings, Inc. v. Autonodyne LLC
Court of Chancery of Delaware, 2024

Cite This Page — Counsel Stack

Bluebook (online)
162 A.3d 102, 2017 WL 2417917, 2017 Del. Ch. LEXIS 95, Counsel Stack Legal Research, https://law.counselstack.com/opinion/organovo-holdings-inc-v-dimitrov-delch-2017.